Orvar™ Autoantigen Discovery Technology

Using conventional methods, it would be necessary to screen every single human protein, splice variant, neoantigen or microbial antigen to discover the total repertoire of autoantigens within a disease.

By using the Orvar™ Autoantigen Discovery Technology, the identity of all the autoantigens and antigens that make up the Autoproteome™ can be discovered. The Autoproteome™ is defined as the totality of all possible autoantigens and neoantigens representing a given disease and its sub-types.

Orvar™ identifies all possible autoantigens and antigens within a human at a given time which are associated with a disease.

Once the Autoproteome™ is identified, we then use our patented KREX™ technology to clone, express and attach every single autoantigen or antigen on to a Sengenics protein array. This customised protein array then serves as a validated, true positive antigen and autoantigen library which is disease-specific. Applications for this protein array include the discovery of autoantibodies for characterisation of diseases either as biomarkers for early diagnostics, protective autoantibodies or intra-disease stratification.

Orvar Autoantigen Discovery Technology | Sengenics Proteomics | Krex Protein Microarrays
Orvar Autoantigen Discovery Technology | Sengenics Proteomics | Krex Protein Microarrays

Orvar™ Case Study

Colorectal Cancer

Study Design:

  • Sample type:
    • Plasma from Colorectal cancer and healthy normal individuals
    • Tissue from Colorectal cancer individuals (cancer and adjacent normal tissue)
  • Platform:
    • Sengenics KREX CT100+ microarray
    • Orvar™ Autoproteome™ Discovery technology


Breakdown of Selected/Identified Antigens

Orvar Autoantigen Discovery Technology | Sengenics Proteomics | Krex Protein Microarrays
Figure 1: Distribution and classification of the top antigens identified in both experiments
  • The Orvar™ technology identified a total of 28 unique autoantigens (Figure 2) which had corresponding autoantibodies present in Colorectal cancer patients;
  • This Orvar™ Colorectal library also led to the discovery of homologues to the antigens eliciting high autoantibody responses on KREX microarrays. These homologues may contain overlapping surface epitopes reactive to these autoantibodies;
  • As all antigens immobilised onto the KREX microarrays are present as wild-type forms, the unique antigens on Orvar™ which are also on KREX microarrays suggests detection of mutated forms of these antigens using the Orvar™ technology.
Orvar Autoantigen Discovery Technology - Case Study | Sengenics Proteomics | Krex Protein Microarrays
Figure 2: GO enrichment analysis for the top 28 unique autoantigens identified using Orvar™


High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389